机构

• 上海药物研究所 [34]
• 工程热物理研究所 [12]
• 力学研究所 [9]
• 上海营养与健康研究所 [6]
• 金属研究所 [4]
• 地球环境研究所 [3]
• 更多

采集方式

• OAI收割 [78]
• iSwitch采集 [2]

内容类型

• 期刊论文 [67]
• 会议论文 [13]

发表日期

• 2025 [1]
• 2023 [5]
• 2022 [2]
• 2021 [4]
• 2020 [4]
• 2019 [9]
• 更多

学科主题

• Biotechnol... [2]
• Research &... [2]
• 其它燃烧问题及燃烧测... [2]
• Biochemist... [1]
• Cell Biolo... [1]
• Chemistry [1]
• 更多

筛选

浏览/检索结果: 共80条，第1-10条 帮助 条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择题名升序题名降序提交时间升序提交时间降序作者升序作者降序发表日期升序发表日期降序 Synthesis and antioxidant evaluation of coumarin-functionalised chitosan: A potent, non-toxic free radical scavenging compound 期刊论文  OAI收割 CARBOHYDRATE RESEARCH, 2025, 卷号: 548, 页码: 11 作者:  Zhu, Siyu;  Miao, Qin;  Chen, Qiuhong;  Tian, Liguang;  Dong, Fang   |  收藏  |  浏览/下载：5/0  |  提交时间：2025/01/10 Chitosan  Coumarins  Antioxidant activity   Erosion Performance of TiAlSiN Coatings Prepared by High-Power Pulsed Magnetron Sputtering 期刊论文  OAI收割 METALS, 2023, 卷号: 13, 期号: 7, 页码: 1306 作者:  Li, Hua;  Li, Liuhe;  Li, Duoduo;  Tang, Ling;  Luo, Yang   |  收藏  |  浏览/下载：23/0  |  提交时间：2023/09/05 erosion resistance  phase composition  TiAlSiN coating  discharge voltages   Carbohydrate Strengthens the Immunotherapeutic Effect of Small-Molecule PD-L1 Inhibitors 期刊论文  OAI收割 JOURNAL OF MEDICINAL CHEMISTRY, 2023, 卷号: 66, 期号: 11, 页码: 7179-7204 作者:  Dong, Qian;  Tong, Mengya;  Yu, Xiaolu;  Wang, Lei;  Ao, Jiwei   |  收藏  |  浏览/下载：39/0  |  提交时间：2023/10/17 Examining moisture contribution for precipitation in response to climate change and anthropogenic factors in Hengduan Mountain Region, China 期刊论文  OAI收割 JOURNAL OF HYDROLOGY, 2023, 卷号: 620, 页码: 129562 作者:  Zhang, Xingxing;  Liu, Zhaofei;  Liu, Yubo;  Jiang, Liguang;  Wang, Rui   |  收藏  |  浏览/下载：23/0  |  提交时间：2023/06/10 tance of YYY  Associate Editor  Hengduan Mountain Region  Moisture source  Climate change  WAM-2layers  Anthropogenic factors   Study on Discharge Characteristics and Microstructural Evolution of PEO Coatings Based on an Al/Ti Tracer Substrate 期刊论文  OAI收割 Coatings, 2023, 页码: 1507 作者:  Li GD(李国栋);  Li G(李光);  Xia Y(夏原)   |  收藏  |  浏览/下载：7/0  |  提交时间：2023/10/13 Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers 期刊论文  OAI收割 AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 卷号: 13, 期号: 1, 页码: 161-+ 作者:  Li, Yongpeng;  Li, Lin;  Fu, Haoyu;  Yao, Qing   |  收藏  |  浏览/下载：19/0  |  提交时间：2023/10/17 Antibody-drug conjugate  DS-8201  PARP  ATR  synergy  DNA damage   Anisotropic linear and nonlinear charge-spin conversion in topological semimetal SrIrO3 期刊论文  OAI收割 PHYSICAL REVIEW B, 2022, 卷号: 106, 期号: 22, 页码: 9 作者:  Lao, Bin;  Liu, Peitao;  Zheng, Xuan;  Lu, Zengxing;  Li, Sheng   |  收藏  |  浏览/下载：22/0  |  提交时间：2023/05/09 Trastuzumab in combination with PEGylated interferon-alpha 1b exerts synergistic antitumor activity through enhanced inhibition of HER2 downstream signaling and antibody-dependent cellular cytotoxicity 期刊论文  OAI收割 AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 卷号: 12, 期号: 2, 页码: 549-561 作者:  Xu, Piaopiao;  Chen, Xiangling;  Xu, Yongping;  Fu, Li;  Li, Yun   |  收藏  |  浏览/下载：173/0  |  提交时间：2022/06/15 Trastuzumab  PEGylated IFN-alpha 1b  ADCC  HER2-positive cancer  synergistic effect   Influence of Applied Frequency on Thermal Physical Properties of Coatings Prepared on Al and AlSi Alloys by Plasma Electrolytic Oxidation 期刊论文  OAI收割 COATINGS, 2021, 卷号: 11, 期号: 12, 页码: 15 作者:  Li GD(李国栋);  Ma, Fei;  Li, Zhijie;  Xu Y(许亿);  Gao FY(高方圆)   |  收藏  |  浏览/下载：78/0  |  提交时间：2022/02/17 PEO  low heat capacity  low heat conductivity  microstructure   Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells 期刊论文  OAI收割 THORACIC CANCER, 2021, 页码: 9 作者:  Zhang, Mi;  Quan, Haitian;  Fu, Li;  Li, Yun;  Fu, Haoyu   |  收藏  |  浏览/下载：65/0  |  提交时间：2021/05/24 EGFR‐  mutant non‐  small cell lung cancer  famitinib  HS‐  10296  multi‐  targeted tyrosine kinase inhibitor  third‐  generation EGFR inhibitor